Clinical trial · Observational
Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma
Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma Treated With Immunotherapy Or Immunochemotherapy And/Or Radiotherapy: An Observational Prospective Study Of The Fondazione Italiana Linfomi
NCT05524298CI-TRIAL-00100675recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 12, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260912-000001
Summary
Brief summary (as posted)
Aims of this study are to describe the variation of QoL (Quality of Life) during the clinical management of low-grade lymphoma in elderly subjects and to identify the most important factors at diagnosis and during treatment with an impact on QoL (Quality of Life).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Low Grade Non-Hodgkin's Lymphoma, Adult | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Elderly Patients With Low Grade Non-Hodgkin Lymphoma
- description
- Elderly Patients With Low Grade Non-Hodgkin Lymphoma Treated With Immunotherapy Or Immunochemotherapy And/Or Radiotherapy. Assess QoL (quality of life) at baseline, at the end of treatment and after 1 year from the start of the therapy.
Primary outcomes (6)
- measure
- QoL (quality of life) scores at baseline - EORTC-QLQ-C30
- timeFrame
- The endpoint wil be evaluated at the baseline.
- description
- Quality of life is measured with the EORTC-QLQ-C30 (European Organisation for Research and Treatment of Cancer-Quality of life Questionnaire-Core 30) questionnaire)
- measure
- QoL (quality of life) scores variations at the end of treatment - EORTC-QLQ-C30
- timeFrame
- The endpoint will be evaluated from the beginning of the study to the end of therapy (up to 18 months)
- description
- Quality of life is measured with the EORTC-QLQ-C30 (European Organisation for Research and Treatment of Cancer-Quality of life Questionnaire-Core 30)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Local histological diagnosis of indolent B cell non-Hodgkin lymphoma: follicular lymphoma, marginal zone lymphoma (nodal, MALT (Mucosa-Associated Lymphoid Tissue), splenic), lymphoplasmacytic lymphoma/ Waldenström macroglobulinemia) * Age ≥ 70 years * Patient candidates to receive treatment for lymphoma * Patient previously untreated for lymphoma * Evaluation of Comprehensive Geriatric Assessment at baseline * Ability to provide informed consent: subject understands and voluntarily signs an informed consent form approved by an IEC (Independent Ethics Committee), prior to registration into the study Note: Patient treated in the context of a clinical trial is admitted Exclusion Criteria: * none
References
Publications (0)
Data not yet available
No reference posted for this study.